Article Details
Retrieved on: 2025-03-13 14:28:11
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details Milestone Pharmaceuticals' development of CARDAMYST, an etripamil nasal spray for A-Fib and PSVT, pending FDA approval. Focused on clinical trials and regulatory compliance, it connects with tags of pharmacology and the pharmaceutical industry, emphasizing market strategies within China's context.
Article found on: qz.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here